IP Library › Granted Patent US 12,274,751
Granted Patent B2
US 12,274,751 · App. 16/707,093 · Granted Apr 15, 2025

Composition and method of the use of colchicine oral liquid

Inventors: Indu Muni (North Reading, MA); Naomi Vishnupad (Reading, MA)
Assignee: RxOMEG Therapeutics LLC
A61K47/36A61K9/0095A61K31/165A61K47/02A61K47/10A61K47/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,274,751
App. No.
16/707,093
Granted
Apr 15, 2025
Kind
B2
Abstract

Oral liquid colchicine formulations are described herein. Methods of using the oral liquid colchicine formulations are also provided.

Claims (6)

1. A method of treating gout, comprising orally administering a composition, comprising a liquid colchicine formulation to a human subject having gout in an effective amount to treat the gout, wherein the liquid colchicine formulation comprises colchicine in an amount of about 0.01-0.015% (w/v) and a pharmaceutically acceptable solvent system comprising water, one or more buffering agents comprising about 0.1-0.3% (w/v) citric acid in combination with about 0.8%-1.6% (w/v) dibasic sodium phosphate, about 2-8% (w/v) propylene glycol, about 0.2%-0.4% (w/v) of benzyl alcohol, optionally one or more sweeteners, optionally one or more flavoring agents, optionally one or more preservatives, and optionally one or more dyes, and wherein the liquid colchicine formulation has a stable pH.

2. The method of claim 1 , wherein the pharmaceutically acceptable solvent system comprises about 1.2% (w/v) dibasic sodium phosphate, heptahydrate.

3. The method of claim 1 , wherein the pharmaceutically acceptable solvent system comprises about 5% (w/v) glycerin USP (99.7%).

4. The method of claim 1 , wherein the pharmaceutically acceptable solvent system comprises about 5% (w/v) propylene glycol.

5. The method of claim 1 , wherein the preservative comprises about 0.3% (w/v) of benzyl alcohol.

6. The method of claim 1 , wherein the thickening agent comprises about 0.1-0.2% (w/v) xanthan gum.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 16, 2019
From: MUNI, INDU; VISHNUPAD, NAOMI
To: RXOMEG THERAPEUTICS LLC
Reel/Frame 051287/0256 →
Continuity (4)
Continuation 15818905 · Nov 21, 2017
Division 15358621 · Nov 22, 2016
Provisional Application 62306232 · Mar 10, 2016
Related Publication 20200108147A1 · Apr 9, 2020
References Cited (80)
US 5668154A · Fink et al. · 1997 [cited by applicant]
US 6140359A · Carver et al. · 2000 [cited by applicant]
US 7601758B1 · Davis · 2009 [cited by applicant]
US 7619004B1 · Davis · 2009 [cited by applicant]
US 7820681B1 · Davis · 2010 [cited by applicant]
US 7906519B2 · Davis · 2011 [cited by applicant]
US 7915269B2 · Davis · 2011 [cited by applicant]
US 7935731B2 · Davis · 2011 [cited by applicant]
US 7964647B2 · Davis et al. · 2011 [cited by applicant]
US 7964648B2 · Davis · 2011 [cited by applicant]
US 7981938B2 · Davis · 2011 [cited by applicant]
US 8093297B2 · Davis · 2012 [cited by applicant]
US 8097655B2 · Davis · 2012 [cited by applicant]
US 8440722B2 · Davis · 2013 [cited by applicant]
US 8927607B1 · Ducharme · 2015 [cited by applicant]
US 9555029B2 · Ducharme · 2017 [cited by applicant]
US 9907751B2 · Muni et al. · 2018 [cited by applicant]
US 10226423B1 · Muni et al. · 2019 [cited by applicant]
US 10383820B2 · Muni et al. · 2019 [cited by applicant]
US 10383821B2 · Muni et al. · 2019 [cited by applicant]
US 11672759B2 · Muni et al. · 2023 [cited by applicant]
US 20030055029A1 · D'Amato et al. · 2003 [cited by applicant]
US 20050153946A1 · Hirsh et al. · 2005 [cited by applicant]
US 20090093548A1 · Mathew et al. · 2009 [cited by applicant]
US 20100179169A1 · Davis · 2010 [cited by applicant]
US 20110229564A1 · Desai et al. · 2011 [cited by applicant]
US 20130274331A1 · Saha et al. · 2013 [cited by applicant]
US 20140107213A1 · Davis · 2014 [cited by applicant]
US 20150057359A1 · Ducharme · 2015 [cited by applicant]
US 20150094317A1 · Ducharme · 2015 [cited by applicant]
US 20150094318A1 · Ducharme · 2015 [cited by applicant]
US 20150094322A1 · Riel et al. · 2015 [cited by applicant]
US 20150094375A1 · Ducharme · 2015 [cited by applicant]
US 20150164831A1 · Roberts · 2015 [cited by examiner]
US 20150196513A1 · Nidorf · 2015 [cited by applicant]
US 20150196514A1 · Nidorf · 2015 [cited by applicant]
US 20150290325A1 · Kashi et al. · 2015 [cited by applicant]
US 20160354396A1 · Mahoney et al. · 2016 [cited by applicant]
US 20170258715A1 · Muni et al. · 2017 [cited by applicant]
US 20180092841A1 · Muni et al. · 2018 [cited by applicant]
US 20180098938A1 · Muni et al. · 2018 [cited by applicant]
US 20180117023A1 · Charles et al. · 2018 [cited by applicant]
US 20190183793A1 · Muni et al. · 2019 [cited by applicant]
US 20190183794A1 · Muni et al. · 2019 [cited by applicant]
US 20200038322A1 · Muni et al. · 2020 [cited by applicant]
US 20230330016A1 · Muni et al. · 2023 [cited by applicant]
CN 101450072A · 2009 [cited by applicant]
CN 102872181A · 2013 [cited by applicant]
CN 105056131A · 2015 [cited by applicant]
WO WO2008021666A2 · 2008 [cited by applicant]
WO WO2009133431A1 · 2009 [cited by applicant]
WO WO2013149109A1 · 2013 [cited by applicant]
WO WO2017156392A1 · 2017 [cited by applicant]
WO WO2018200143A2 · 2018 [cited by applicant]
Habib et. al. (Drug Development and Industrial Pharmacy (1989) 15:1905-1909) (Year: 1989). [cited by examiner]
International Search Report and Written Opinion for Application No. PCT/US2017/021777 mailed Jun. 21, 2017. [cited by applicant]
International Preliminary Report on Patentability for Application No. PCT/US2017/021777 mailed Sep. 20, 2018. [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/US2018/066943 mailed Apr. 3, 2019. [cited by applicant]
Extended European Search Report for Application No. EP17764180 mailed Oct. 11, 2019. [cited by applicant]
[No Author Listed], Colchicine Injection, USP. Bedford Laboratories. 1999. 2 pages. [cited by applicant]
[No Author Listed], Colchicine Product Information. Cayman Chemicals. Dec. 5, 2011. 1 page. [cited by applicant]
[No Author Listed], Colchicine Product Information. Sigma-Aldrich, Inc. 2003. 2 pages. [cited by applicant]
Artursson et al., Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv Drug Deliv Rev. Mar. 1, 2001;46(1-3):27-43. Review. [cited by applicant]
Habib et al., Influence of certain additives on the photostability of colchicine solutions+. Drug Development and Industrial Pharmacy. 1989; 15(11):1905-9. [cited by applicant]
Krishna et al., Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers. Clin Ther. Feb. 2009;31(2):286-… [cited by applicant]
Rask et al., Cochicine use in 6000 patients with disk disease & other related resistantly-painful spinal disorders. J of Neurolog & Orthopaedic Medicine & Surgery. Dec. 1989; 10(4):291-8. [cited by applicant]
Shen et al., Improvement of colchicine oral bioavailability by incorporating eugenol in the nanoemulsion as an oil excipient and enhancer. Int J Nanomedicine. 2011;6:1237-43. doi: 10.2147/IJN.S20903. Epub Jun. 20, 2011. [cited by applicant]
Stewart et al., Comparison of intestinal permeabilities determined in multiple in vitro and in situ models: relationship to absorption in humans. Pharm Res. May 1995;12(5):693-9. [cited by applicant]
Yee, In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man—fact or myth. Pharm Res. 1997; 14(6):763-3. [cited by applicant]
Yu et al., Biopharmaceutics classification system: the scientific basis for biowaiver extensions. Pharm Res. Jul. 2002;19(7):921-5. [cited by applicant]
U.S. Appl. No. 15/818,905, filed Nov. 21, 2017, Muni et al. [cited by applicant]
U.S. Appl. No. 15/834,514, filed Dec. 7, 2017, Muni et al. [cited by applicant]
U.S. Appl. No. 16/544,607, filed Aug. 19, 2019, Muni et al. [cited by applicant]
PCT/US20117/021777, Jun. 21, 2017, International Search Report and Written Opinion. [cited by applicant]
PCT/US20117/021777, Sep. 20, 2018, International Preliminary Report on Patentability. [cited by applicant]
PCT/US2018/066943, Apr. 3, 2019, International Search Report and Written Opinion. [cited by applicant]
EP17764180, Oct. 11, 2019, Extended European Search Report. [cited by applicant]
International Preliminary Report on Patentability for Application No. PCT/US2018/066943 mailed Jul. 2, 2020. [cited by applicant]
PCT/US2018/066943, Jul. 2, 2020, International Preliminary Report on Patentability. [cited by applicant]
U.S. Appl. No. 18/308,841, filed Apr. 28, 2023, Muni et al. [cited by applicant]
Cited By (1)
US 12,514,819